» Articles » PMID: 19476653

Inter-observer Reproducibility of HER2 Immunohistochemical Assessment and Concordance with Fluorescent in Situ Hybridization (FISH): Pathologist Assessment Compared to Quantitative Image Analysis

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2009 May 30
PMID 19476653
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In breast cancer patients, HER2 overexpression is routinely assessed by immunohistochemistry (IHC) and equivocal cases are subject to fluorescent in situ hybridization (FISH). Our study compares HER2 scoring by histopathologists with automated quantitation of staining, and determines the concordance of IHC scores with FISH results.

Methods: A tissue microarray was constructed from 1,212 invasive breast carcinoma cases with linked treatment and outcome information. IHC slides were semi-quantitatively scored by two independent pathologists on a range of 0 to 3+, and also analyzed with an Ariol automated system by two operators. 616 cases were scorable by both IHC and FISH.

Results: Using data from unequivocal positive (3+) or negative (0, 1+) results, both visual and automated scores were highly consistent: there was excellent concordance between two pathologists (kappa = 1.000, 95% CI: 1-1), between two machines (kappa = 1.000, 95% CI: 1-1), and between both visual and both machine scores (kappa = 0.898, 95% CI: 0.775-0.979). Two pathologists successfully distinguished negative, positive and equivocal cases (kappa = 0.929, 95% CI: 0.909-0.946), with excellent agreement with machine 1 scores (kappa = 0.835, 95% CI: 0.806-0.862; kappa = 0.837, 95% CI: 0.81-0.862), and good agreement with machine 2 scores (kappa = 0.698, 95% CI: 0.6723-0.723; kappa = 0.709, 95% CI: 0.684-0.732), whereas the two machines showed good agreement (kappa = 0.806, 95% CI: 0.785-0.826). When comparing categorized IHC scores and FISH results, the agreement was excellent for visual 1 (kappa = 0.814, 95% CI: 0.768-0.856), good for visual 2 (kappa = 0.763, 95% CI: 0.712-0.81) and machine 1 (kappa = 0.665, 95% CI: 0.609-0.718), and moderate for machine 2 (kappa = 0.535, 95% CI: 0.485-0.584).

Conclusion: A fully automated image analysis system run by an experienced operator can provide results consistent with visual HER2 scoring. Further development of such systems will likely improve the accuracy of detection and categorization of membranous staining, making this technique suitable for use in quality assurance programs and eventually in clinical practice.

Citing Articles

Reproductive factors and expression of stem cell markers in women with incident benign breast disease.

Wang T, Heng Y, Sardella B, Rosner B, Tamimi R, Yaghjyan L Am J Cancer Res. 2024; 14(11):5434-5445.

PMID: 39659919 PMC: 11626268. DOI: 10.62347/KLAC9365.


Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer.

Ko H, Seager R, Pabla S, Senosain M, Van Roey E, Gao S Breast Cancer (Dove Med Press). 2024; 16:483-495.

PMID: 39192887 PMC: 11348991. DOI: 10.2147/BCTT.S476394.


Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.

Yaghjyan L, Heng Y, Baker G, Murthy D, Mahoney M, Rosner B Br J Cancer. 2024; 131(2):325-333.

PMID: 38849477 PMC: 11263693. DOI: 10.1038/s41416-024-02743-2.


Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer.

Peg V, Moline T, Roig M, Saruta Y, Cajal S Diagn Pathol. 2024; 19(1):32.

PMID: 38360676 PMC: 10868098. DOI: 10.1186/s13000-024-01455-8.


Enhancing the anticancer potential of metformin: fabrication of efficient nanospanlastics, cytotoxic studies on HEP-2 cells and reactome enhanced pathway analysis.

Raafat S, Abd El Wahed S, Badawi N, Saber M, Abdollah M Int J Pharm X. 2023; 6:100215.

PMID: 38024451 PMC: 10630776. DOI: 10.1016/j.ijpx.2023.100215.


References
1.
Ellsworth R, Ellsworth D, Patney H, Deyarmin B, Love B, Hooke J . Amplification of HER2 is a marker for global genomic instability. BMC Cancer. 2008; 8:297. PMC: 2571108. DOI: 10.1186/1471-2407-8-297. View

2.
Tsuda H, Sasano H, Akiyama F, Kurosumi M, Hasegawa T, Yoshiyuki Osamura R . Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int. 2002; 52(2):126-34. DOI: 10.1046/j.1440-1827.2002.01327.x. View

3.
Garcia-Caballero T, Menendez M, Vazquez-Boquete A, Gallego R, Forteza J, Fraga M . HER-2 status determination in breast carcinomas. A practical approach. Histol Histopathol. 2005; 21(3):227-36. DOI: 10.14670/HH-21.227. View

4.
Tsuda H, Tani Y, Hasegawa T, Fukutomi T . Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma. Pathol Int. 2001; 51(1):26-32. DOI: 10.1046/j.1440-1827.2001.01163.x. View

5.
Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L . Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol. 2005; 29(11):1505-11. DOI: 10.1097/01.pas.0000172294.67409.4f. View